EMA and Swissmedic agree on further Cooperation
Recommendation

17/18 June 2026
Copenhagen, Denmark
Supervision of the Pharmaceutical Quality System: Challenges and Opportunities
The European Medicines Agency (EMA), the Directorate General Health and Food Safety (DG SANTE) of the European Commission and the Swissmedic signed an agreement which aims at ensuring a better exchange of non-public information for the protection of the public health. It is intended to exchange information related to the safety, quality or efficacy of medicines which are either already approved or in the authorisation process in the EU or in Switzerland. A similar agreement existed in 2009/2010 at the time of the H1N1 pandemic. The new agreement has been effective since the 10 July 2015 and will be valid for five years.
To find out more please see the original note on the page of the Swissmedic.
Related GMP News
29.05.2026European QP Association Developments January through April 2026
15.04.2026ICH Q9 Training Package updated
01.04.2026New EMA GMP Guidelines in the next three Years
01.04.2026New EMA Guidance: Risk Management for Elemental Impurities in Veterinary Medicinal Products
18.03.2026Sampling in the Focus of the FDA
11.03.2026EU Pharma Package: Final Texts officially published


